MK0869 and MK0517 Time-on-Target PET Study.
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Aprepitant (Primary) ; Fosaprepitant (Primary) ; Dexamethasone; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting; Nausea and vomiting; Postoperative nausea and vomiting
- Focus Pharmacokinetics
- Sponsors Merck & Co
- 02 Nov 2011 Primary endpoint identified as Neurokinin-1 receptor occupancy as reported by ClinicalTrials.gov.
- 08 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.